TrialBMC medicine2022

Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial.

Zhaoqing Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.